LivTech specializes in cutting edge research of novel therapeutic antibodies, covering exploration of target molecules, generation of antibodies, evaluation of antibody activity and selection of lead products for clinical development.
LivTech’s R&D is focused on anti-cancer therapeutics and the company is committed to devote all of its expertise and efforts to contribute to the global fight against cancer.
LivTech’s primary scope of activities is in research targeted at identifying new therapeutic antibodies. Lead product candidates will be licensed to pharmaceutical companies for clinical development, and LivTech will receive financial rewards in upfront fees, milestone and royalty payments.
